Form 4: Eliem Therapeutics Director Judith Dunn Acquires 10,000 Stock Options
SEC Form 4 Filing
Director Judith Dunn acquired 10,000 stock options in Eliem Therapeutics, Inc. on June 26, 2024.
Summary
- Judith Dunn, a director of Eliem Therapeutics, Inc., reported a transaction on June 26, 2024.
- She acquired 10,000 stock options with an exercise price of $7.89.
- These options vest on the earlier of June 26, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
- Following the transaction, Ms. Dunn directly owns 10,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider confidence is generally positive, this is a routine transaction.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, engages in a transaction involving the company's securities. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Date of transaction: Judith Dunn acquired 10,000 stock options. |
| 06/26/2025 | Vesting date: Options vest on the earlier of this date or the day before the next annual meeting of stockholders, subject to continuous service. |
| 06/25/2034 | Expiration date: Stock options expire on this date. |
| 06/28/2024 | Date of signature: Form 4 signed by William Cowles, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.